C

Cutia Therapeutics
HKEX:2487

Watchlist Manager
Cutia Therapeutics
HKEX:2487
Watchlist
Price: 6 HKD -3.07% Market Closed
Market Cap: 2.2B HKD

Cutia Therapeutics
Cash & Cash Equivalents

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Cutia Therapeutics
Cash & Cash Equivalents Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash & Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
C
Cutia Therapeutics
HKEX:2487
Cash & Cash Equivalents
ÂĄ385.7m
CAGR 3-Years
24%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Cash & Cash Equivalents
ÂĄ12.2B
CAGR 3-Years
-21%
CAGR 5-Years
26%
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Cash & Cash Equivalents
ÂĄ9.5B
CAGR 3-Years
92%
CAGR 5-Years
132%
CAGR 10-Years
N/A
Akeso Inc
HKEX:9926
Cash & Cash Equivalents
ÂĄ6.9B
CAGR 3-Years
38%
CAGR 5-Years
42%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Cash & Cash Equivalents
ÂĄ2.4B
CAGR 3-Years
19%
CAGR 5-Years
54%
CAGR 10-Years
N/A
S
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
HKEX:6990
Cash & Cash Equivalents
ÂĄ1.5B
CAGR 3-Years
135%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Cutia Therapeutics
Glance View

Market Cap
2.2B HKD
Industry
Biotechnology

Cutia Therapeutics is a holding company that engages in the research and development of dermatology treatment solutions and products through its subsidiaries. The company is headquartered in Shanghai, Shanghai and currently employs 175 full-time employees. The company went IPO on 2023-06-12. The firm is committed to developing comprehensive solutions to meet the diverse needs of patients and consumers in a wide range of dermatological treatment and care markets. The firm is mainly engaged in clinical trials of its core product CU-20401. This product is mainly used to treat submental fat accumulation. The firm conducts its businesses in the domestic market and overseas markets.

Intrinsic Value
13.69 HKD
Undervaluation 56%
Intrinsic Value
Price
C

See Also

What is Cutia Therapeutics's Cash & Cash Equivalents?
Cash & Cash Equivalents
385.7m CNY

Based on the financial report for Dec 31, 2024, Cutia Therapeutics's Cash & Cash Equivalents amounts to 385.7m CNY.

What is Cutia Therapeutics's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 3Y
24%

Over the last year, the Cash & Cash Equivalents growth was -18%. The average annual Cash & Cash Equivalents growth rates for Cutia Therapeutics have been 24% over the past three years .

Back to Top